EU and US set to take regulatory relationship further
This article was originally published in RAJ Devices
Executive Summary
The EU and US medicines agencies are set to renew and intensify their co-operation in the field of medicines regulation. Meeting in London on 30 September and 1 October this year, the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) agreed that the confidentiality arrangements that have already been in place for five years, have been a resounding success, thereby encouraging them to expand their collaboration in existing as well as new areas, including advanced therapy medicines, nanotechnology-derived medicinal products and the exchange of pharmacovigilance information.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.